Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-IL17 (Ixekizumab) in new-onset type 1 diabetes
2019-001188-58Phase 2Active
- Sponsor
- University of Gothenburg
- Start
- Sep 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in diabetes mellitus type 1 (T1D) comparing Ixekizumab with Placebo (2 arms). Primary endpoint: Change in stimulated C-peptide AUC over 2 hours (MMTT) from baseline to week 52. Started Sep 2020; status: active.
02
Drugs
ixekizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2019-001188-58.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001188-58.